The Association of British Clinical Diabetologists

Compatibility and safety of faster-acting insulin aspart used in continuous subcutaneous insulin infusion therapy in patients with type 1 diabetes

Adrenocortical Insufficiency in a Patient with Stable Liver Cirrhosis

Significant reduction of hypoglycaemia in patients with type 1 diabetes with insulin degludec compared with insulin glargine U100: a randomised, doubleblind, crossover trial (SWITCH 1)

Joint meeting with Renal Association 28th February 2017

The 3rd Joint Meeting of the Association of British Clinical Diabetologists
and the Renal Association
Diabetes and Kidney Disease: Advances and Controversies

Audit on the management of microalbuminuria in people with type 2 diabetes in secondary care

Assessing the Prevalence of Cardiovascular Risk Factors amongst Patients with Diabetes and Chronic kidney disease

Audit of secondary care diabetes and renal follow up in patients with moderate to severe CKD

Anti-diabetic therapy in patients with type 2 diabetes & chronic renal impairment

Three-times-weekly insulin therapy: the Hammersmith haemodialysis experience

Three-times-weekly insulin therapy: the Hammersmith haemodialysis experience

Compatibility and safety of faster-acting insulin aspart used in continuous subcutaneous insulin infusion therapy in patients with type 1 diabetes

Adrenocortical Insufficiency in a Patient with Stable Liver Cirrhosis

Significant reduction of hypoglycaemia in patients with type 1 diabetes with insulin degludec compared with insulin glargine U100: a randomised, doubleblind, crossover trial (SWITCH 1)

Joint meeting with Renal Association 28th February 2017

Audit on the management of microalbuminuria in people with type 2 diabetes in secondary care

Assessing the Prevalence of Cardiovascular Risk Factors amongst Patients with Diabetes and Chronic kidney disease

Audit of secondary care diabetes and renal follow up in patients with moderate to severe CKD

Anti-diabetic therapy in patients with type 2 diabetes & chronic renal impairment

Three-times-weekly insulin therapy: the Hammersmith haemodialysis experience

Three-times-weekly insulin therapy: the Hammersmith haemodialysis experience

Search the Association of British Clinical Diabetologists